In agreement with previous results, 27.7% of CD20-positive DLBCL patients in the present study had a high expression of Ki-67; however, in the current study, 70.8% of CD20-negative DLBCL patients had a high proliferation index (Ki-67 ≥ 80%). This evidence concerns the gene MKI67 and diffuse large B-cell lymphoma.